KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) Other Operating Expenses (2017 - 2026)

Moderna (MRNA) has disclosed Other Operating Expenses for 9 consecutive years, with $955.0 million as the latest value for Q1 2026.

  • For Q1 2026, Other Operating Expenses rose 961.11% year-over-year to $955.0 million; the TTM value through Mar 2026 reached $1.7 billion, up 18.86%, while the annual FY2025 figure was $868.0 million, 40.71% down from the prior year.
  • Other Operating Expenses hit $955.0 million in Q1 2026 for Moderna, up from $452.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $2.2 billion in Q3 2023 and bottomed at $90.0 million in Q1 2025.
  • Average Other Operating Expenses over 5 years is $788.0 million, with a median of $739.0 million recorded in 2024.
  • Year-over-year, Other Operating Expenses plummeted 87.88% in 2024 and then surged 961.11% in 2026.
  • Moderna's Other Operating Expenses stood at $1.9 billion in 2022, then crashed by 51.56% to $929.0 million in 2023, then fell by 20.45% to $739.0 million in 2024, then tumbled by 38.84% to $452.0 million in 2025, then soared by 111.28% to $955.0 million in 2026.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $955.0 million, $452.0 million, and $207.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.